Prognos, an AI-powered analytics for early tracking and prediction of disease, today announced that it will partner with Datavant, the company helping healthcare organizations safely connect their data. Prognos will be able to harness Datavant’s comprehensive ecosystem in delivering analytics solutions, expanding the data that customers can readily access to better inform clinical decisions, identify risk, enhance care quality, and improve patient outcomes.
In order to determine and predict trends in disease progression, healthcare companies need to go beyond traditional medical claims and Rx data sets to get a more rounded and timely view of the patient. Today’s healthcare companies require ready access and linking to the latest lab-based AI solutions, clinical expertise, and advanced algorithms to drive best actions earlier in the patient journey.
Prognos is the only company that has created a standardized view of laboratory results across multiple national and regional labs in a registry composed of nearly 24 billion records, covering 200 million patients across more than 50 disease conditions. In connection with the partnership, Datavant will be acquiring Prognos’ OPAL product, which is the leading de-identification solution for diagnostic data. OPAL users will be seamlessly migrated into Datavant’s ecosystem, making it easy to connect data with hundreds of other Datavant partners.
The partnership strengthens Prognos’ analytics offering, expands possibilities for early tracking and prediction of disease, and gives Prognos’ existing data source partners and customers the option to connect their data to Datavant’s open data ecosystem.
“As the amount of healthcare data exponentially increases, so does our potential for predicting disease and its trajectory, which enables us to get the right treatment and care to the right patient, at the right time,” said Prognos CEO and Co-Founder, Sundeep Bhan. “Partnering with Datavant will be a force multiplier to Prognos’ analytical capabilities by leveraging Datavant’s ecosystem to expand our existing data partnerships across data types. Giving our customers a more comprehensive view of the patient will result in better and more forward-looking insights to improve decision-making.”